Global Gene Therapy for Inherited Genetic Disorders Market 2019-2023

 PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

• Market segmentation by application
• Comparison by application
• Eye disorders - Market size and forecast 2018-2023
• Hematological disorders - Market size and forecast 2018-2023
• Central nervous system disorders - Market size and forecast 2018-2023
• Muscular disorders - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC SEGMENTATION

• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

• Market trends

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• BioMarin Pharmaceutical Inc.
• bluebird bio Inc.
• Novartis AG
• Orchard Therapeutics Plc
• Spark Therapeutics Inc.

PART 14: APPENDIX

• Research methodology
• List of abbreviations
• Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO